
News|Articles|April 6, 2026
Q1 2026 Recap: Top FDA Approvals
Author(s)HCPLive Editorial Staff
Fact checked by: Abigail Brooks, MA
A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.
Advertisement
Advertisement
The first quarter of 2026 brought a series of notable US Food and Drug Administration (FDA) approvals, highlighting continued momentum in innovation across diverse therapeutic areas, including rare diseases, endocrinology, dermatology, psychiatry, and hepatology. A recurring theme was the expansion of treatment options for underserved populations, particularly pediatric and rare disease communities, alongside a growing emphasis on more convenient, patient-centered care.
Related to this article

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
Advertisement
Advertisement

